Please login to the form below

Not currently logged in
Email:
Password:

elotuzumab

This page shows the latest elotuzumab news and features for those working in and with pharma, biotech and healthcare.

FDA clears first-line use for J&J

FDA clears first-line use for J&J

Market research firm Persistence reckons Darzalex and another therapeutic antibody – Roche’s Empliciti (elotuzumab) – which “will not only provide a new treatment option for multiple myeloma patients, but they will also

Latest news

  • FDA clears first-line use for J&J’s myeloma drug Darzalex FDA clears first-line use for J&J’s myeloma drug Darzalex

    Market research firm Persistence reckons Darzalex and another therapeutic antibody – Roche’s Empliciti (elotuzumab) – which “will not only provide a new treatment option for multiple myeloma patients, but they will also

  • AbbVie's PARP inhibitor veliparib fails to deliver AbbVie's PARP inhibitor veliparib fails to deliver

    AbbVie will draw comfort from its stake in three fast-growing blood cancer drugs - Imbruvica (ibrutinib), Venclexta (venetoclax) and Empliciti (elotuzumab) - and several mid-stage candidates including antibody drug conjugates (ADCs)

  • Amgen's Kyprolis tops Velcade in myeloma trial Amgen's Kyprolis tops Velcade in myeloma trial

    Multiple myeloma is becoming increasingly competitive, however, thanks to new launches such as Bristol-Myers Squibb's Empliciti (elotuzumab), Novartis' Farydak (panobinostat) and Johnson &Johnson's Darzalex (daratumumab).

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    Takeda's orally-active proteasome inhibitor Ninlaro (ixazomib), Novartis' HDAC inhibitor Farydak (panobinostat) and Bristol-Myers Squibb's SLAMF7 inhibitor Empliciti (elotuzumab) are all jostling for market share with Darzalex at

  • Amgen's Kyprolis scarred by head-to-head duel with Velcade Amgen's Kyprolis scarred by head-to-head duel with Velcade

    Meanwhile other new myeloma drugs - including Johnson &Johnson's anti-CD38 antibody Darzalex (daratumumab) and Bristol-Myers Squibb's SLAMF7 inhibitor Empliciti (elotuzumab) - are also expected to compete strongly with Kyprolis

More from news
Approximately 6 fully matching, plus 23 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics